PubMed Health⌕ Search

Biomedical subjects

R S May

Publications and source records attributed to R S May.

5 recordsLinked to original sources
PubMed2000

Platelet activation in depression and effects of sertraline treatment: An open-label study.

OBJECTIVE: The authors' goal was to determine whether sertraline attenuates the increased platelet activation seen among depressed patients. METHOD: They tested 21 otherwise healthy patients with untreated major depressive episode who were 25-52 years old and 21 age- and sex-matched comparison subjects. Patients received 6 weeks of sertraline treatment, and 17 returned for retesting. RESULTS: At baseline, the depressed patients had greater platelet secretion than the comparison subjects in response to collagen. Depressed patients with a family history of coronary disease had nonsignificantly greater wound-induced fibrinogen receptor binding than the other subjects. Platelet secretion in response to collagen was significantly reduced after treatment with sertraline. CONCLUSIONS: Sertraline diminished the increased platelet secretion found among depressed patients, although the findings are limited by a lack of a placebo control group.

Adult↗
PubMed1981

N-formimidoyl thienamycin (MK0787): in vitro study.

N-Formimidoyl thienamycin (MK0787) was compared in vitro with three other beta-lactam and two aminoglycoside antibiotics. It was second in activity only to cefotaxime against members of the Enterobacteriaceae and to amikacin against Pseudomonas species. It was the most active antibiotic against Staphylococcus aureus. Resistance (minimal inhibitory concentration, greater than 128 microgram/ml) to N-formimidoyl thienamycin was not observed.

Anti-Bacterial Agents↗
PubMed1980

A spectral unfolding method to determine source depth distribution.

The depth distribution in tissue of a gamma-emitting isotope can be estimated by observing the energy spectrum of photons emerging from the body. Monte Carlo methods were used to compute surface energy spectra for 99Tcm point sources at various depths. From these noise-free results a discrete response matrix was constructed to relate the input source depth to the corresponding output spectrum. Observed spectra with noise were then simulated independently by Monte Carlo calculations assuming various measurement times and source strengths. The source distribution was determined by solving the discrete inverse unfolding problem by the Method of Regularisation. The effective depth resolution is seen to depend strongly upon measurement time. The results show that limited depth resolution can be obtained from a single view of the object region.

Monte Carlo Method↗
PubMedDate not supplied

Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study.

UNLABELLED: The objective of this study was to determine whether the aminoketone antidepressant bupropion has beneficial effects in orgasmic dysfunction. DESIGN: Single-blind, sequential treatment order of three weeks each: placebo, bupropion-SR 150 mg/day, bupropion-SR 300 mg/day. SUBJECTS: Nondepressed women (n = 20) and men (n = 10) having nonphysiologic orgasmic delay or inhibition. MAIN OUTCOME MEASURES: Reported difficulty or delay in achieving orgasm, satisfaction with orgasm and erectile function, and subjective impressions of drug effect. RESULTS: In the women, there were significant improvements relative to baseline (p < .01) on both doses of bupropion-SR in all measured aspects of sexual function, and significant improvements relative to placebo (p < .05) in overall sexual satisfaction on both doses and satisfaction with intensity of orgasm on 150 mg/day (300 mg/day, p = .10). In the men, significant improvements over baseline (p < .01) were observed with both doses in overall sexual satisfaction, ability to achieve an erection, and delay in reaching orgasm/ejaculation; significant improvements relative to placebo (p < .05) were observed in overall sexual satisfaction on both doses, ability to achieve erection on 150 mg/day, and delay in orgasm/ejaculation on 150 mg/day. Seventy percent of subjects reported improvement in libido, arousal, or orgasmic function during bupropion administration. CONCLUSIONS: Bupropion-SR may be a useful agent for treating orgasmic delay and inhibition, and possibly disorders of sexual arousal. The results argue against bupropion's apparent prosexual effect in depressed patients being simply a result of its antidepressant activity.

Adult↗